...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>European journal of neurology: the official journal of the European Federation of Neurological Societies >MxA protein--an interferon beta biomarker in primary progressive multiple sclerosis patients.
【24h】

MxA protein--an interferon beta biomarker in primary progressive multiple sclerosis patients.

机译：MxA蛋白-原发性进行性多发性硬化症患者中的干扰素β生物标志物。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND AND PURPOSE: Interferon beta (IFNbeta) preparations have some effect on the progressive phase of multiple sclerosis (MS). This limited effect might be partially because of a certain number of IFNbeta non-responders. Myxovirus resistance protein A (MxA)--a marker of IFNbeta bioactivity--was correlated with the clinical response during an uncontrolled trial, investigating the safety of IFNbeta-1b in primary progressive (PPMS) patients. METHODS: Twenty PPMS were treated with IFNbeta-1b (s.c.) for 1 year. Blood samples were taken before and 1, 2, 3, 6, 9, 12, and 15 months after treatment initiation and MxA protein levels were measured. Patients were clinically evaluated by EDSS and the more sensitive Incapacity Status Scale (ISS) and stratified in a stable and a progressing group. RESULTS: Using ISS criteria, 11 patients remained stable and nine patients progressed during treatment. The mean area under the curve of log MxA levels during treatment were significantly higher in stable than in progressing patients (10.87 vs. 5.99; P = 0.002). CONCLUSION: A good biological response to IFNbeta might be associated with a better clinical effect of this drug and could be helpful in future clinical studies for early identification of treatment responders.
机译：背景与目的：干扰素β（IFNbeta）制剂对多发性硬化症（MS）的进展期有一定影响。这种有限的作用可能部分是由于一定数量的IFNbeta无反应。在一项非对照试验中，研究了粘液病毒抗性蛋白A（MxA）-IFNbeta生物活性的标志物-与临床反应相关，研究了IFNbeta-1b在原发性进行性（PPMS）患者中的安全性。方法：20例PPMS用IFNbeta-1b（s.c.）治疗1年。在治疗开始之前和之后1、2、3、6、9、12和15个月采集血样，并测量MxA蛋白水平。通过EDSS和更敏感的“无行为能力状态量表”（ISS）对患者进行临床评估，并将其分为稳定的和进展中的一组。结果：使用ISS标准，治疗期间11名患者保持稳定，9名患者进展。稳定患者的log MxA水平曲线下的平均面积明显高于进展中患者（10.87 vs. 5.99; P = 0.002）。结论：对IFNβ的良好生物学反应可能与该药物的较好临床疗效有关，并且可能有助于将来的临床研究以早期识别治疗反应者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号